Key Points
- CEO Jurgi Camblong sold 4,486 shares on March 19 at an average of $4.77 for $21,398.22, leaving him with 3,302,839 shares (a 0.14% ownership decrease valued at about $15.75M).
- SOPHiA GENETICS reported a quarterly EPS loss of ($0.28), missing estimates by $0.08, and showed a negative net margin of 44.22% and negative ROE of 50.60%, indicating continued unprofitability.
- Shares trade near $4.96 with a market cap of ~$340M; analysts have a consensus "Hold" rating and a $7.00 price target, though individual ratings range from buy to sell.
SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) CEO Jurgi Camblong sold 4,486 shares of the stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $4.77, for a total value of $21,398.22. Following the completion of the transaction, the chief executive officer owned 3,302,839 shares of the company's stock, valued at $15,754,542.03. This represents a 0.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
SOPHiA GENETICS Stock Performance
Shares of SOPH stock opened at $4.96 on Friday. The firm has a market capitalization of $339.71 million, a price-to-earnings ratio of -9.73 and a beta of 1.13. The company has a current ratio of 1.96, a quick ratio of 1.84 and a debt-to-equity ratio of 1.01. The business's 50-day moving average price is $4.87 and its 200-day moving average price is $4.53. SOPHiA GENETICS SA has a 12 month low of $2.58 and a 12 month high of $5.70.
SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last released its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.08). The firm had revenue of $21.71 million during the quarter, compared to analyst estimates of $21.20 million. SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. Equities research analysts forecast that SOPHiA GENETICS SA will post -0.96 EPS for the current year.
Institutional Trading of SOPHiA GENETICS
Several institutional investors have recently added to or reduced their stakes in the stock. Savvy Advisors Inc. acquired a new stake in SOPHiA GENETICS during the 3rd quarter valued at approximately $48,000. Perkins Capital Management Inc. acquired a new position in shares of SOPHiA GENETICS in the 4th quarter worth approximately $49,000. Squarepoint Ops LLC bought a new stake in shares of SOPHiA GENETICS in the 3rd quarter valued at $49,000. Quadrature Capital Ltd bought a new stake in shares of SOPHiA GENETICS in the 4th quarter valued at $54,000. Finally, XTX Topco Ltd acquired a new stake in shares of SOPHiA GENETICS during the fourth quarter worth $55,000. 31.59% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Several research firms have recently issued reports on SOPH. Guggenheim raised their price target on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the company a "buy" rating in a research note on Monday, January 26th. Weiss Ratings restated a "sell (d-)" rating on shares of SOPHiA GENETICS in a report on Thursday, January 22nd. Finally, BTIG Research reaffirmed a "buy" rating and set a $7.00 target price on shares of SOPHiA GENETICS in a research report on Tuesday, March 3rd. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, SOPHiA GENETICS presently has a consensus rating of "Hold" and a consensus target price of $7.00.
Read Our Latest Stock Report on SOPHiA GENETICS
About SOPHiA GENETICS
(
Get Free Report)
SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.
The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
